How much does stem cell therapy for ALS (Motor Neurone Disease) cost? (2026)
The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 65 ALS (Motor Neurone Disease) records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.
Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem and motor cortex. Multiple mechanisms are under investigation, including excitotoxicity, mitochondrial dysfunction, protein misfolding and neuroinflammation. Neural progenitor and mesenchymal stromal cell approaches are being studied for proposed neuroprotective or supportive effects, but these mechanisms have not established slowed progression or restored motor function in people. The registry table on this page lists relevant studies and their current recruitment status.
What drives the cost for ALS (Motor Neurone Disease)
Private investigational ALS cell procedures can involve separate charges for intrathecal administration, neurological and respiratory assessment, imaging, monitoring, travel and treatment of complications. Prices do not indicate regulatory approval or expected benefit, and repeat dosing is not an established standard. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Multidisciplinary ALS care and approved or guideline-supported treatment must not be delayed.
Human ALS cell-therapy studies are generally early-phase and heterogeneous, with different products, routes, populations and endpoints. Safety observations and exploratory biomarker changes do not establish slower functional decline or longer survival. No completed pivotal trial has established a stem-cell product as effective standard ALS treatment. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
ALS (Motor Neurone Disease) cost by country — comparison (2026)
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | Verify provider and laboratory certificates |
| USA | €4,600–€46,000 | Non-EU; verify provider and product status |
| UK | €4,880–€49,000 | Non-EU; verify provider and product status |
| Germany | €11,000–€36,700 | EU member state; verify provider and product status |
| Switzerland | €20,000–€40,000 | Non-EU; verify provider and product status |
| Mexico | €3,000–€12,000 | Non-EU; verify provider and product status |
| India | €3,000–€8,000 | Non-EU; verify provider and product status |
| Serbia | €7,000–€31,000 | Non-EU; verify provider and product status |
| Turkey | €6,000–€18,000 | Non-EU; verify provider and product status |
| Thailand | €8,000–€20,000 | Non-EU; verify provider and product status |
| Panama | €15,000–€27,000 | Non-EU; verify provider and product status |
Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.
ALS (Motor Neurone Disease) cost — common questions
Why is ALS (Motor Neurone Disease) stem-cell treatment so much cheaper in Bulgaria?
The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.
Is a cheaper programme riskier?
Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.
Does the price include travel and hotel?
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
Will I get a fixed quote, or an open-ended bill?
Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for ALS (Motor Neurone Disease) (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.